Vascular Disruptive Agents in Combination with Radiotherapy

摘要: Despite early promise, clinical trials of single agent VDAs have not demonstrated the ability to consistently produce significant tumour shrinkage or durable remissions. Contributing this effect is persistence viable residual rim following treatment with a VDA and provides strong rationale for combining them other anti-cancer strategies, including radiotherapy. With evidence suggesting that overall anti-tumour radiotherapy in part related resultant damage vasculature, additional support these two therapeutic modalities. As described chapter, preclinical phase date can improve index through improved effect, spatial cooperation non-overlapping toxicities. There remains scope further effects produced by combination Strategies shown promise when combined irradiation include hyperthermia, bioreductive agents vascular directed therapies.